Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38

被引:43
|
作者
David, C [1 ]
Kikuta, T [1 ]
Somogyvari-Vigh, A [1 ]
Arimura, A [1 ]
机构
[1] Tulane Univ, Sch Med, US Japan Biomed Res Labs, Dept Med, New Orleans, LA 70112 USA
关键词
pituitary adenylate cyclase-activating polypeptide (PACAP); subpicomole; signaling; activity-dependent neuroprotective protein (ADNP); neuroprotection;
D O I
10.1385/JMN:27:01:91
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In neuronal/glial cocultures, pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) prevented neuronal death induced by gp120, lipopolysaccharide (LPS), or other toxic agents, but the dose response of the neuroprotective effect is bimodal, with a peak at a subpicomolar concentration and another peak at a subnanomolar to nanomolar concentration. Although the signaling cascade involved in neuroprotection by nanomolar concentration of the peptide has been shown to be mediated by activation of cAMP-dependent protein kinase and subsequent activation of mitogen-activated protein kinase (MAPK), the mechanism for neuroprotection. by a subpicomolar level of PACAP38 remains elusive. In the present study, the signaling involved in neuroprotection by subpicomolar PACAP38 was studied in rat neuronal/glial cocultures. Addition of PACAP38 stimulated expression and activation of extracellular signal-related kinase-type MAPK with a peak response at 10(-13) M; greater concentrations of the peptide induced lesser response. cAMP production also increased at subpicomolar levels of PACAP38, but the level remained unchanged at a level four to five times higher than the base level at concentrations below 10(-11) M. cAMP then started increasing again dose-dependently in a range > 10(-11) MPACAP38. Lipopolysaccharide (LPS)-induced neuronal death, indicated by increased release of neuron-specific enolase, was suppressed by PACAP38 in a bimodal fashion. Neuroprotection by 10(-12) M PACAP38 was completely abolished by a MAPK kinase-1 inhibitor, PD98059, and also partially suppressed by Rp-cAMP, a cAMP-dependent protein kinase inhibitor. Moreover, neuroprotection by a nanomolar level of PACAP38 was completely suppressed by Rp-cAMP but not affected by PD98059. We conclude that neuroprotection by subpicomolar PACAP38 is mainly mediated by the signaling pathway involving MAPK activation and partially regulated by cAMP-dependent protein kinase activation. Furthermore, PACAP38 stimulated expression of activity-dependent neuroprotective protein (ADNP), with a peak at 10(-13) M. Greater doses of the peptide induced lesser response. However, 10(-13) M PACAP38-stimulated expression of ADNP was not affected by PD98059. This suggests that neuroprotection by subpicomolar PACAP38 might be mediated partially by expression of ADNP, but the major events for neuroprotection by subpicomolar PACAP38 remain to be identified.
引用
收藏
页码:91 / 105
页数:15
相关论文
共 50 条
  • [1] Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38
    Min Li
    Csaba David
    Toshiteru Kikuta
    Aniko Somogyvari-Vigh
    Akira Arimura
    Journal of Molecular Neuroscience, 2005, 27 (1) : 91 - 105
  • [2] Pituitary adenylate cyclase-activating polypeptide
    Gonzalez, BJ
    Basille, M
    Vaudry, D
    Fournier, A
    Vaudry, H
    ANNALES D ENDOCRINOLOGIE, 1998, 59 (05) : 364 - 405
  • [3] Pituitary adenylate cyclase-activating polypeptide
    Li, XL
    Zhao, XX
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2001, 28 (02) : 140 - 144
  • [4] Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression
    Nakamachi, Tomoya
    Li, Min
    Shioda, Seiji
    Arimura, Akira
    PEPTIDES, 2006, 27 (07) : 1859 - 1864
  • [5] Behavioural action of pituitary adenylate cyclase-activating polypeptide-38
    Adamik, A
    Pataki, I
    Telegdy, G
    JOURNAL OF PHYSIOLOGY-LONDON, 2000, 526 : 189P - 189P
  • [6] Distribution of pituitary adenylate cyclase-activating polypeptide and pituitary adenylate cyclase-activating polypeptide type I receptor mRNA in the chicken brain
    Peeters, K
    Gerets, HHJ
    Arckens, L
    Vandesande, F
    JOURNAL OF COMPARATIVE NEUROLOGY, 2000, 423 (01) : 66 - 82
  • [7] Neuroprotection: A comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
    Brenneman, Douglas E.
    PEPTIDES, 2007, 28 (09) : 1720 - 1726
  • [8] Intracrine pharmacology of pituitary adenylate cyclase-activating polypeptide
    Doan, N. D.
    Nguyen, T. T. M.
    Letourneau, M.
    Vaudry, D.
    Vaudry, H.
    Chatenet, D.
    Fournier, A.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 48 : S161 - S161
  • [9] Pituitary adenylate cyclase-activating polypeptide and adrenomedullary function
    Skott, O
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2003, 284 (02) : R586 - R587
  • [10] Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia
    R Hashimoto
    H Hashimoto
    N Shintani
    S Chiba
    S Hattori
    T Okada
    M Nakajima
    K Tanaka
    N Kawagishi
    K Nemoto
    T Mori
    T Ohnishi
    H Noguchi
    H Hori
    T Suzuki
    N Iwata
    N Ozaki
    T Nakabayashi
    O Saitoh
    A Kosuga
    M Tatsumi
    K Kamijima
    D R Weinberger
    H Kunugi
    A Baba
    Molecular Psychiatry, 2007, 12 : 1026 - 1032